Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kruithof

Showing results (221-230 of 493) with videos related to

Pageof 50
Sort By:
British Journal of Clinical Pharmacology|December 1, 1981
RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteersM Burnier, G A Turini, H R Brunner, et al.
Arthritis and Rheumatism|June 30, 2005
Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritisLeen De Rycke, Dominique Baeten, Elli Kruithof, et al.
Drugs|November 26, 2004
Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitisFilip De Keyser, Dominique Baeten, Filip Van den Bosch, et al.
Healthcare (Basel, Switzerland)|January 10, 2026
From Hidden Insights to Better Understanding: Physicians' Perspectives on Caregivers' Tacit KnowledgeSylvia A Huisman, Kasper Kruithof, Maartje Hoogsteyns, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 24, 2010
Influence of microneedle shape on the transport of a fluorescent dye into human skin in vivoSuzanne M Bal, Annelieke C Kruithof, Raphaël Zwier, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1990
Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cellsJ F Cajot, J Bamat, G E Bergonzelli, et al.
British Journal of Clinical Pharmacology|April 7, 2020
The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy male volunteersSebastiaan C Goulooze, Annelieke C Kruithof, Shanavas Alikunju, et al.
Arthritis and Rheumatism|March 29, 2002
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathyFilip Van Den Bosch, Elli Kruithof, Dominique Baeten, et al.
Water Research|October 13, 2016
The role of natural organic matter in nitrite formation by LP-UV/H<sub>2</sub>O<sub>2</sub> treatment of nitrate-rich waterSofia Semitsoglou-Tsiapou, Astrid Mous, Michael R Templeton, et al.
JACC. Basic to Translational Science|September 19, 2024
A New Ex Vivo Model to Study Cardiac Fibrosis in Whole Mouse HeartsBoudewijn P T Kruithof, Babak Mousavi Gourabi, Arjanneke F van de Merbel, et al.
Pageof 50

Showing results (221-230 of 493) with videos related to

Sort By:
Pageof 50
British Journal of Clinical Pharmacology|December 1, 1981
RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteersM Burnier, G A Turini, H R Brunner, et al.
Arthritis and Rheumatism|June 30, 2005
Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritisLeen De Rycke, Dominique Baeten, Elli Kruithof, et al.
Drugs|November 26, 2004
Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitisFilip De Keyser, Dominique Baeten, Filip Van den Bosch, et al.
Healthcare (Basel, Switzerland)|January 10, 2026
From Hidden Insights to Better Understanding: Physicians' Perspectives on Caregivers' Tacit KnowledgeSylvia A Huisman, Kasper Kruithof, Maartje Hoogsteyns, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 24, 2010
Influence of microneedle shape on the transport of a fluorescent dye into human skin in vivoSuzanne M Bal, Annelieke C Kruithof, Raphaël Zwier, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1990
Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cellsJ F Cajot, J Bamat, G E Bergonzelli, et al.
British Journal of Clinical Pharmacology|April 7, 2020
The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy male volunteersSebastiaan C Goulooze, Annelieke C Kruithof, Shanavas Alikunju, et al.
Arthritis and Rheumatism|March 29, 2002
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathyFilip Van Den Bosch, Elli Kruithof, Dominique Baeten, et al.
Water Research|October 13, 2016
The role of natural organic matter in nitrite formation by LP-UV/H<sub>2</sub>O<sub>2</sub> treatment of nitrate-rich waterSofia Semitsoglou-Tsiapou, Astrid Mous, Michael R Templeton, et al.
JACC. Basic to Translational Science|September 19, 2024
A New Ex Vivo Model to Study Cardiac Fibrosis in Whole Mouse HeartsBoudewijn P T Kruithof, Babak Mousavi Gourabi, Arjanneke F van de Merbel, et al.
Pageof 50